DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Oliner KS, Douillard JY, Siena S. et al.
Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).
J Clin Oncol 2013
31. abstr 3511
Access:
We do not assume any responsibility for the contents of the web pages of other providers.